Registration for the symposium is not yet open.
Sign up to receive updates.
Suresh S. Ramalingam, MD, has been named executive director of Winship Cancer Institute of Emory University. A thoracic oncologist and physician scientist, Dr. Ramalingam has served as Winship's deputy director since 2016. He will preside over the largest expansion in Winship's history, including construction of a 17-story cancer facility, and he will lead the institute as it seeks renewal of its National Cancer Institute designation.
Patient Resource Navigator provides the tools to guide patients through their care continuum. This leading-edge platform offers one-to-one patient education guides and apps, created with specific content for each patient’s diagnosis and treatment plan. System-provided metrics assist in demonstrating patient-centered care, meeting accreditation standards and developing marketplace differentiation.
Sidney and Caroline Kimmel have been selected by the AACI Board of Directors to receive the 2021 AACI Champion for Cures Award, which recognizes transformational philanthropy that advances our shared vision of a future without cancer. Karen Knudsen, MBA, PhD, former SKCC director, AACI past president, and current CEO of the American Cancer Society, will virtually present the award to the Kimmels during the 2021 AACI/CCAF Annual Meeting in October.
There is still time to register for the 13th Annual AACI CRI Meeting, July 13-15. The virtual meeting will provide an innovative and quality educational experience that aligns with AACI’s strategic goal of stimulating cancer center interactions to maximize resources by creating opportunities for peer-to-peer networking and collaboration. Highlights include a session titled "Community Outreach and Engagement: Knowing Your Catchment Area."
AACI's Physician Clinical Leadership Initiative (PCLI) will host The Role of the Clinical Pharmacist in an Academic Hematology/Oncology Practice at 2:00 pm eastern time on Tuesday, August 24. This webinar will cover the clinical pharmacist (CP) training and supervision requirements along with roles and responsibilities.
AACI cancer centers are encouraged to endorse a statement recently issued by the Comprehensive Cancer Center at St. Jude Children's Research Hospital, calling for the resumption of the human papillomavirus (HPV) vaccine among adolescents in the United States. The COVID-19 pandemic has profoundly interrupted delivery of key preventive services, resulting in many U.S. adolescents missing routine HPV vaccine doses.
On Wednesday, June 9, AACI co-hosted the 2021 Virtual Hill Day with the American Association for Cancer Research (AACR). Ninety-three cancer center directors, researchers, oncologists, survivors, and other advocates, representing 26 states, attended meetings with legislators and staff to present a unified voice in support of stable funding increases for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
Christine Lovly, MD, PhD, is the recipient of the 2021 ECOG-ACRIN Young Investigator Award. She is co-leader of the Translational Research and Interventional Oncology Program at Vanderbilt-Ingram Cancer Center.
A veteran diagnostic radiologist and nuclear physician, Roswell Park Comprehensive Cancer Center’s Alan Klitzke, MD, FACNM, has been named a fellow of the American College of Radiology (ACR). Recognition as a fellow is the highest level of ACR membership, with only 10 percent of members awarded this distinction.
Vanessa B. Sheppard, PhD, was recently conferred the 2021 Women in Science, Dentistry and Medicine Professional Achievement Award from the VCU School of Medicine. She is associate director for community outreach, engagement and health disparities at VCU Massey Cancer Center.
Duke Cancer Institute (DCI) neurosurgeon-scientist Peter Fecci, MD, PhD, has been inducted into the American Society for Clinical Investigation (ASCI). At DCI he serves as director of the Duke Center for Brain and Spine Metastasis and associate deputy director of the Preston Robert Tisch Brain Tumor Center.
The Bladder Cancer Advocacy Network has recognized Benjamin Miron, MD, a medical oncology fellow at Fox Chase Cancer Center, with the 2021 New Discoveries Young Investigator Award.
Tuya Pal, MD, associate director for cancer health disparities at Vanderbilt-Ingram Cancer Center and Ingram Professor of Cancer Research, has been named a Komen Scholar. Dr. Pal specializes in genomics and health disparities across populations, including a focus on the outcomes of early onset breast cancer in Black women.
The National Cancer Institute has awarded the Lung Cancer Metabolism Working Group at Moffitt Cancer Center more than $10.2 million. The grant will support team research across several programs, including Cancer Biology and Evolution, Molecular Medicine and Immuno-Oncology. Elsa Flores, PhD, is principal investigator.
Research and treatment of head and neck cancers at the University of Colorado Cancer Center have reached a new level with a highly competitive Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute. The grant is for $2 million per year for five years.
A five-year, $2.8 million grant from the National Cancer Institute will support a new University of Kentucky College of Medicine study examining how policies that restrict the sale of flavored tobacco products including menthol cigarettes impact health disparities among vulnerable populations.
The Donald W. Reynolds Institute on Aging at the University of Arkansas for Medical Sciences has been awarded a five-year, $1.9 million grant from the National Institute on Aging. The project, led by Steven Barger, PhD, will focus on glucose transporter cells and their inability to deliver glucose to the brain in patients with Alzheimer’s disease.
Andrew E. Aplin, PhD, has been named deputy director for scientific strategy of the Sidney Kimmel Cancer Center (SKCC) at Jefferson Health. Dr. Aplin, who is the associate director for basic research at SKCC and the Kalbach-Newton Professor in Cancer Research, assumed the role on June 1.
Lauren Hackett, MPA, has been appointed the deputy director of administration of Albert Einstein Cancer Center and associate vice president of cancer medicine at Montefiore Medicine. Currently the chief operating officer at the Allen Institute, Hackett will assume her new roles in August.
Mount Sinai Health System has recruited an internationally recognized expert in the management of breast cancer and HIV-associated malignancies, Joseph A. Sparano, MD, FACP, as chief of Hematology and Medical Oncology and deputy director of The Tisch Cancer Institute.
Thoracic medical oncologist Sukhmani K. Padda, MD, recently was selected to direct Thoracic Medical Oncology at Cedars-Sinai Cancer. She joins Cedars-Sinai from Stanford University.
Caroline Powers has been named senior vice president for external affairs at Dana-Farber Cancer Institute. She joins Dana-Farber from the American Cancer Society Cancer Action Network (ACS CAN), where she served as senior director of federal relations.
The University of Michigan Rogel Cancer Center has named two new assistant directors to help facilitate and enhance its community outreach and engagement efforts. Elena Stoffel, MD, MPH, will be assistant director of cancer disparities outreach, and Lawrence An, MD, will be assistant director for cancer screening and prevention.
Albert Einstein Cancer Center (AECC), Albert Einstein College of Medicine, and Montefiore Health System have announced that Julio Aguirre-Ghiso, PhD, has been named founding director of the Cancer Dormancy and Tumor Microenvironment Institute, director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program.
Shanta Laurie Garvin MHSA, MPA, CRA, has joined Duke Cancer Institute as director of Research Development-Clinical Research. In her new role she will lead and manage activities to enhance processes, prepare for continued growth, assure staff development, and expand communication with investigators, among other duties.
Marcus Bosenberg, MD, PhD, has been named the inaugural director of the Yale Center for Immuno-Oncology. He is contact principal investigator of the Yale SPORE (Specialized Program of Research Excellence) in skin cancer, and director of the Center for Precision Cancer Modeling.
Amy Jo Jenkins, MS, CCRP, recently joined the Winthrop P. Rockefeller Cancer Institute’s new Office of Clinical Trials Administration and will lead the early phase clinical trials at the University of Arkansas for Medical Sciences (UAMS). She is immediate past president of the board of directors for the Society of Clinical Research Associates.
Luisa Iruela-Arispe, PhD, a vascular biologist, has been named co-leader of the Tumor Environment and Metastasis Program at the Robert H. Lurie Comprehensive Cancer Center. The goal of the program is to elucidate how interactions between tumor cells, immune cells, and components of the host stromal microenvironment impact tumor development and progression.
Bringing more than two decades of experience in the fields of population health and cancer prevention and control, Linda Cook, PhD, will join the University of Colorado Cancer Center in July as associate director of population sciences. She will join the leadership team overseeing the CU Cancer Center’s Cancer Prevention & Control Program.
The University of Michigan Rogel Cancer Center has named Erika Newman, MD, its first associate director for diversity, equity, inclusion and justice. She will lead the center’s efforts to diversify the next generation of health care professionals and researchers, and to champion an anti-racist and just culture within the cancer center.
Seeing an opportunity to safely reduce the number of opioid doses prescribed to patients undergoing surgery, gynecologic oncologist Emese Zsiros, MD, PhD, FACOG, proposed a new pain-management guideline for all patients undergoing surgery at Roswell Park Comprehensive Cancer Center.
Researchers at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School have discovered a phage display-based approach to halt tumor growth that could be used to treat triple-negative breast cancer.
Stanford researchers have discovered that the level of certain proteins in the eye could predict survival risk in patients with uveal melanoma. The researchers hope the discovery will not only aid in disease monitoring but could also lead to therapies tailored to individual patients.
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1 percent objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
A recent FDA-approved treatment for non-small cell lung cancer rests on a foundation of UCSF research. This long-delayed milestone might not have happened without the work of Kevan Shokat, PhD, who revitalized a holy-grail-like quest after almost all others had given up.
Through a pre-clinical study conducted in his former role at Moffitt Cancer Center, Said Sebti, PhD, associate director for basic research at VCU Massey Cancer Center, discovered a vulnerability of pancreatic tumors addicted to the cancer-causing mutant KRAS gene and identified a drug that effectively thwarts these tumors.
A new study is the first to demonstrate that the inherited risk of early-onset cancer is significantly higher among Latino and African American families for solid tumors, and Asian/Pacific Islander families for blood-based cancers, compared to non-Latino white families in California.
A revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine, according to a study led by researchers at Yale Cancer Center, Stony Brook University, and KDx Diagnostics, Inc.
Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at the Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a platform to guide immunotherapy by predicting which cancers will respond to therapies targeting the immune system.
Researchers in Lerner Research Institute’s Department of Cancer Biology have identified a promising drug target for treating and preventing drug-resistant prostate cancer. The team is led by Nima Sharifi, MD.
New research shows that treatment with immune checkpoint inhibitors has led to a significant improvement in survival and response rates among patients with advanced sarcomatoid renal cell carcinoma. The study was led by a team from Roswell Park Comprehensive Cancer Center and involved contributors from six centers.
Researchers with the University of Florida’s academic health center have collaborated with NVIDIA to create GatorTron™, an artificial intelligence transformer natural language processing model intended to accelerate research and medical decision-making by extracting insights from massive volumes of clinical data with unprecedented speed and clarity.
A treatment regimen for patients with advanced melanoma that combines the immunotherapy agents relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) delayed time to cancer progression significantly more than nivolumab alone, according to results of a study led by Evan Lipson, MD.
A new study of a cancer hospital-at-home model operated by Huntsman Cancer Institute found a reduction in costs and unplanned health care visits for participants in the program. Kathleen Mooney, PhD, RN, led the study.
Researchers from the University of Illinois Urbana-Champaign have turned their gaze to the natural world to develop a camera inspired by the mantis shrimp that can visualize cancer cells during surgery.
A study headed by Lovoria B. Williams, PhD, assistant director for cancer health equity at the Markey Cancer Center, highlights the benefits of utilizing community health workers in educating racial minority populations in lung cancer screening.
A new study led by investigators at Sidney Kimmel Cancer Center at Jefferson Health and collaborators in Texas, England, and Australia, has revealed key aspects of how a cellular signaling pathway contributes to advanced disease progression, focusing on castrate-resistant lethal prostate cancer.
A new clinical trial at The Ohio State University Comprehensive Cancer Center offers women with certain forms of early-stage breast cancer and inherited genetic risk factors a new breast cancer surgery option with potential to result in improved cosmetic outcomes without compromising cancer control and recurrence risk.
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia, according to researchers at The University of Texas MD Anderson Cancer Center.
A team from the University of Illinois Urbana-Champaign’s Grainger College of Engineering and Mayo Clinic have developed a technique for creating "microcancer" cell cultures. It allows researchers to form hundreds of microcancers in a high-throughput format using a small, microfabricated chip, enabling direct measurement of cell health or response to drugs.
Chongzhi Zang, PhD, and his colleagues and students have developed a new computational method to map the folding patterns of our chromosomes in three dimensions from experimental data. As part of the work, they’ve built an interactive website that brings together their findings with data from other resources.
Stanford researchers had found that the injection of iPS cells and adjuvant therapy into laboratory mice could prevent the formation of cancers when the animals were subsequently injected with mouse breast cancer, skin cancer, or mesothelioma cells. That finding has been extended to include mice injected with mouse pancreatic cancer cells.
Emerging evidence suggests that e-cigarettes can be a helpful tool in smoking cessation. Researchers in Moffitt Cancer Center’s Tobacco Research and Intervention Program have built upon this evidence by testing whether they could help dual users, people who use both combustible cigarettes and e-cigarettes, quit smoking.
UC San Francisco is launching a new initiative to propel the development of living therapeutics—a category of treatments broadly defined as human and microbial living cells that are selected, modified, or engineered to treat or cure disease—and bring them quickly to patients.
A new study led by Wendi O’Neill, DDS, and Quintin Pan, PhD, found that African American patients with oropharyngeal squamous cell carcinoma (OPSCC) have significantly shorter overall survival than European American OPSCC patients, even when the groups have similar access to medical care.
If it's 10:00 am central time Wednesday, a smiling Roy Jensen, MD, is most likely greeting his cyberguests for another episode of Bench to Bedside. Dr. Jensen, director of The University of Kansas Cancer Center and immediate past president of AACI, hosts the Facebook Live series that uses a talk-show format to cover a broad range of topics related to cancer.
RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, in partnership with the New Brunswick Development Corporation, have broken ground on the state’s first freestanding cancer hospital. The 12-story facility will be named the Jack and Sheryl Morris Cancer Center.
NJ Spotlight News interviewed AACI Past President Stanton L. Gerson, MD, about the significance of providing services to cancer patients near where they live. Jersey City Medical Center has opened a new infusion facility in partnership with Rutgers Cancer Institute of New Jersey, an AACI member.
The $31 million Senator Orrin G. Hatch Proton Therapy Center at Huntsman Cancer Institute has opened. It is one of only 37 such centers nationwide. According to the National Cancer Institute, nearly half of all cancer patients receive some type of radiation therapy.
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is advancing proton therapy care for patients by adding the latest, most innovative technology to its S. Lee Kling Proton Therapy Center.Stephanie M. Perkins, MD, directs the center.